

## EliV5 Therapeutics

4G Earls Ct, Farmington, CT 06032

### Company Contact:

T 860-906-7302

www.eliv5therapeutics.com

Email: cbmamoun@eliv5therapeutics.com



### Industry: Biotech

#### Management:

##### • Executive Leadership

##### Choukri Ben Mamoun:

- Founder & CEO EliV5 Tx
- Associate Professor of Medicine & Microbial Pathogenesis at Yale
- 28 years of research experience
- 19 years as an Independent Investigator
- 87 peer reviewed publications
- 23 funded grants (NIH, DOD and foundations) in 19 years – 5 currently active (3 NIH RO1s and 2 PITCH grants)

##### • Board: To Be Named

##### • Scientific Advisory Board: To Be Named

#### Use of Funds:

- 1 Scientist
- 1 Program Manager
- 1 Medicinal Chemist
- 1 Physician Consultant, Yale ID doctor
- 1 scientist consultant with expertise in the genetic manipulation of pathogenic fungi
- 1 MBA consultant for regulatory and legal advice

#### Finance:

- Current Investors / Financing to Date: \$438,870 from Program in Therapeutics for Connecticut Health: Project Period: 09/01/2017 – 12/31/2019
- Amount of Financing Sought: \$1.8M (Total for 3 years) Milestones: Identify clinical candidate
- 1 NIH STTR revision will be on April 5, 2019
- 1 NIH SBIR New Submission will be submitted on September 5, 2019

**IP:** Provisional submitted to Yale OCR in February 2019

### Executive Summary:

The long-term mission of EliV5 Therapeutics is to produce first-in-class drugs to treat fungal infections and address the global need for more potent and safer drugs that are also effective against drug-resistant fungal pathogens. EliV5 is seeking funds to advance these compounds through preclinical and clinical evaluations, and capture 10 to 50% of the global antifungal market.

### Company History:

- Founded May 16, 2018
- Technology developed in the Ben Mamoun Lab at Yale School of Medicine
- Completed a screen of ~131,000 compounds against the target
- Discovered 4 new classes of inhibitors: highly selective and biologically active
- Initial funding from PITCH

### Unmet Need: (*Benedict et al., CID 2018; Zilberger et al., CID 2018*)

- 1.5M annual deaths due to fungal infections worldwide with 97,000 deaths in the US caused primarily by *Candida* and *Aspergillus* species.
- ~15,000 Aspergillosis-associated and ~27000 candidiasis-associated hospitalizations occur in the US annually with a combined cost of ~ \$2.6B
- Global Antifungal Market: ~\$11.3B in 2017; to reach \$19.5B - \$23B in 2023 ([www.marketresearchfuture.com](http://www.marketresearchfuture.com); [www.grandviewresearch.com](http://www.grandviewresearch.com))
- Despite available therapies, mortality rates range between 10% and 95%.
- Drug resistance is a major problem and increasing at an alarming rate.
- No therapies that achieve radical cure are currently available.

### Products/Services –Pipeline:

#### First-in-class drugs:

- Identified 4 new classes of small molecule inhibitors with enzyme selectivity against the pathogen's enzyme (4Q18)
- Our compounds inhibit master regulator of fungal metabolism and survival

#### 1-2 Punch Therapeutic Strategy:

- Monotherapy
- Synergistic combination with known anti-fungals to achieve radical cure with reduced toxicity

**Goal:** Identify lead clinical candidate(s) Phase I in 2022 and market launch 2027

### Technical Milestones:

Optimize the best chemical class and Identify lead clinical candidate(s) (4Q21)  
Complete preclinical evaluation of the lead compounds (4Q21)  
Define ideal antifungal indication - IND filing - Engage potential partners (2Q22)

### Competition:

1. Mortality rates for candidiasis are 10 to 75% and for aspergillosis 30 to 95%.
2. Drug resistance to azoles (~\$6B global market) approaches 15% in Europe.
3. Azoles and other antifungals are associated with major adverse events.

### Financial Projections (Unaudited): revenue Aspergillosis+Candidiasis:

1 year in the market: \$260M - \$400M      5 years out: \$1.3B - \$2B CAGR: 4.5%